8-KEarnings & ResultsRegulation FDExhibits & Filings

DEXCOM INC 8-K Report, Financial Results (Jan 9, 2018)

Filed January 9, 2018For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on January 9, 2018, providing preliminary, unaudited results for the fourth quarter of 2017 and offering forward-looking guidance. The company is referencing a corporate presentation (Exhibit 99.01) which contains these details and is available on their website. This filing supplements information previously disclosed in an 8-K filed on January 8, 2018, and provides additional color on expected performance metrics. Investors should note that these preliminary results are subject to finalization in the upcoming Form 10-K. The company explicitly states that the information furnished is not deemed "filed" and is not incorporated by reference into other SEC filings, limiting its liability. Key aspects for investors revolve around the preliminary Q4 2017 financial performance and the forward-looking guidance for fiscal year 2018. While specific figures for Q4 are not detailed within the text of the 8-K itself, the document directs investors to the attached presentation for these crucial operational and financial updates, including expected revenue, gross margin, operating expenses, and growth in sensor volumes, international revenue, and patient base. This filing highlights DexCom's proactive communication regarding its performance and future outlook.

Key Highlights

  • 1DexCom filed an 8-K on January 9, 2018, containing preliminary, unaudited Q4 2017 results and forward-looking guidance.
  • 2The primary source of detailed financial and operational information is a corporate presentation (Exhibit 99.01) attached to the filing and available on DexCom's investor relations website.
  • 3This 8-K supplements information previously disclosed on January 8, 2018.
  • 4The company provides forward-looking guidance for fiscal year 2018, including expectations for revenue, gross margin, operating expenses, and growth metrics.
  • 5Preliminary Q4 2017 results are subject to finalization and will be included in the upcoming Form 10-K.
  • 6Information furnished in this report is not deemed "filed" for Section 18 purposes and is not incorporated by reference into other SEC filings.
  • 7The filing highlights expected growth in sensor volumes, international revenue, and patient base for 2018.

Frequently Asked Questions

The main purpose of this 8-K filing is to provide investors with preliminary, unaudited financial results for the fourth quarter of 2017 and to offer updated forward-looking guidance for fiscal year 2018. The detailed information is presented in an accompanying corporate presentation.

The specific preliminary results for Q4 2017 and the forward-looking guidance for FY 2018 are contained in Exhibit 99.01, a Corporate Presentation, which is attached to this 8-K filing. It is also available on DexCom's investor relations website.

No, the Q4 2017 results presented are preliminary and unaudited. They are subject to finalization as DexCom prepares its Annual Report on Form 10-K for the period ended December 31, 2017.

This specific 8-K filing focuses on financial results and forward-looking guidance. It does not mention any new product announcements or significant business developments within the provided text, but the corporate presentation might contain further details.